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The objective. was to investigate L-Carnitine level and the eﬀects of its supplementation in children with moderate persistent
Asthma. Methods. Free and total serum carnitine levels were measured in 50 children having moderate persistent asthma and 50
healthy control children. The patients group was randomly divided into two subgroups. Subgroup A was supplemented with L-
Carnitinefor6monthswhilesubgroupBwasusedasaplacebocontrols.Bothsubgroupswereassessedbypulmonaryfunctiontests
(PFT) and childhood-asthma control test (C-ACT) before and 6 months after carnitine supplementation. Results. Total and free
carnitine levels were signiﬁcantly lower in patient group than in control group. PFT and C-ACT showed signiﬁcant improvements
in asthmatic children supplemented with L-Carnitine than in those who were not supplemented. Conclusion. L-Carnitine levels
were initially lower in moderate persistent asthmatic children as compared to healthy control children. Asthmatic children who
received L-Carnitine supplementation showed statistically signiﬁcant improvement of C-ACT and PFT.
1.Introduction
Asthma is a common complex chronic inﬂammatory disor-
der of the airways characterized by variable and recurring
symptoms, airﬂow obstruction, bronchial hyper responsive-
ness, and an underlying inﬂammation. It is one of the most
common chronic diseases of childhood, aﬀecting more than
6 million children and more than 22 million persons in
the United States [1]. The persistence or increase of asthma
symptoms over time is accompanied by a progressive decline
in lung functions [2]. The patho physiology of persistent
asthma remains poorly understood. Even with the current
therapies, the symptoms may be incompletely controlled, or
they might have little eﬀect on disease process [3, 4]. As
pharmacologic therapy may have variable results in these
asthmatic children, the search for metabolic or nutritional
deﬁciencies contributing to the disease has continued. In
instances where metabolic or nutritional deﬁciencies are a
contributingfactortoongoinginﬂammatoryprocessesinthe
bronchial tree, dietary supplementation of these deﬁciencies
may provide beneﬁt [5].
L-Carnitine is a cofactor that plays an essential role in the
mitochondrial oxidation of long-chain fatty acids. It spares
muscle glycogen, improves tolerance to physical activity,
and reduces muscle fatigue [6]. It has been noted that L-
Carnitine decreases leukotriene synthesis through inhibition
of lipoxygenase enzyme [7]. L-Carnitine administration is
beneﬁcial to exercise and respiratory strength training in
outpatients with stable, moderate-to-severe chronic obstruc-
tive pulmonary diseases [8]. L-Carnitine supplementation
canincreaseserumcarnitinelevels,improveexercisecapacity
andcorrecttheobstructivepatterninbreathfunctiontestsin
certain diseases [7, 9].
The role of L-Carnitine in development or persistence
of pediatric asthma has not been investigated. This paper
investigated the diﬀerences in serum L-Carnitine levels2 Journal of Allergy
in pediatric asthmatic patients as compared to healthy
control children. In addition, it studied the eﬀectiveness
of L-Carnitine supplementation in improving symptom
scores and pulmonary function testing in children moderate
persistent pediatric asthma.
2. Study Patients
The study included 77 children between 6 and 12 years
of age and diagnosed to have moderate persistent asthma.
TheywererecruitedfromtheAllergyandPulmonologyUnit,
Paediatric Departments, New Children Hospital, Faculty of
Medicine, Cairo University, Egypt. They were invited to
participate in the study from March 2008 till May 2009. Fifty
children out of 77 children completed the study, 10 refused
to complete the study (as they were not able to swallow L-
Carnitine capsules), and 17 failed to adhere to the study pro-
tocol (eight of them did not show up at the follow-up visits,
5 children did not take the asthma medications on a regular
basis, and 4 suﬀered from infections during the pre study
phase). Those 50 children were further randomly subdivided
into two equal subgroups (A or B). Fifty healthy children of
matched age and sex were included as a control group.
3. Deﬁnition of Moderate Persistent Asthma
The children were deﬁned as having moderate persistent
asthma according to National Heart, Lung, and Blood
Institute Guidelines, if they have daily symptoms, night-
time awakenings more than 1time/week but not nightly,
some limitation of the normal activities, Forced Expiratory
Volume in 1 second (FEV1) 60–80% of the predicted,
Forced Expiratory Volume in 1second/Forced Vital Capacity
Ratio (FEV1/FVC) 75–80% of the predicted, daily use of a
quick-relief inhaler, and/or exacerbations requiring systemic
corticosteroids equal to or more than twice a year [1]. The
standard care was allowed to be altered up or down during
the supplementation phase according to the child condition.
4. Exclusion Criteria
(1) Any pulmonary or chronic systemic diseases other
than asthma and rhinitis, for example, cystic ﬁbrosis,
bronchiectasis, tuberculosis, diabetes mellitus, and
liver.
(2) Children with immunodeﬁciency or history of pre-
mature birth.
(3) Children with hypothyroidism or borderline thyroid
functions.
(4) Other medications that may aﬀect carnitine level:
antibiotics use (particularly Ampicillins) and anti-
convulsants for example Valproic acid.
(5) Recent exhaustion, infection (especially pneumonia),
surgery, anaesthesia.
(6) Children who failed to have regular outpatient
follow-up visits, a reliable caregiver, and willingness
to complete at least 1 outpatient visit per month,
and those who were not adherent to proper asthma
medications.
5.Methodology
5.1. Study Design. There were two phases of the study;
pre-clinical phase and active study phase during which
children with moderate persistent asthma were recruited.
During the 6-month preclinical phase the asthma control
test, frequency of use of short acting B2 agonists, use of
shortcoursesofsystemicsteroids,thefrequencyofnighttime
symptoms, frequency of acute asthma exacerbation, and the
need for emergency department visit or hospitalization were
recorded. During this phase every eﬀort was done to max-
imize the asthma control and to decrease the severity of the
asthmawiththeuseofstepupregimenaccordingtoNational
Heart, Lung, and Blood Institute Guidelines [1]. Children
followupanddatacollectionweredoneatmonthlyintervals.
T h ea c t i v es t u d yp h a s ew a sc o n d u c t e da sar a n d o m -
ized, double-blind, placebo-controlled trial over 6 con-
secutive months. The children were randomly allocated
using computer-generated list of random numbers. At the
beginning phase of this study, the total and free plasma
carnitine levels were assessed in both the patient and control
groups. One blood sample was collected from each of the
control group, and two samples were collected from the
asthmatic children; the ﬁrst sample was obtained during
acute asthma exacerbation, and the second was obtained
three weeks after the attack. We considered the mean of the 2
samples for analysis.
The patient group was further subdivided into two sub-
groups. Subgroup A (n = 25) received L-Carnitine 350mg
capsules, 3 capsules each morning for 6 months. Subgroup
B( n = 25) received 3 placebo identical appearing capsules
containing lactose for a similar time. The parents were
strictly instructed to supervise their children while taking
the capsules and to report the occurrence of diarrhoea or
gastric upset as a sign of overdose. In addition, children were
instructed to swallow and not to bite or chew the capsules.
The children were checked at least once a month. They
would also visit the clinic if they developed exacerbations or
ifitwasnecessarytomaximizetheasthmacontrol.Recording
of the childhood-asthma control test, the frequency of use
of short acting B2 agonists, use of short courses of systemic
steroids, the frequency of night time symptoms, frequency
of acute asthma exacerbation, and the need for emergency
department visit or hospitalization were also done as well
as any side eﬀects related to the medications including
L-Carnitine. At the end of the study, the total and the
free plasma carnitine levels were reassessed in the patient
subgroups.
Serum total and free carnitine levels were studied by the
enzymatic spectrophotometric method (Shimadzu UV160A
spectrophotometer, Japan). A venous blood sample was
withdrawn from each child on serum gel blood-collection
tubes (Sarstedt). The obtained samples were centrifuged at
3000×g for 15 minutes, and serum samples were kept at
−20◦C until analysis. Serum total and free carnitine levelsJournal of Allergy 3
Table 1: Demographic data and associated comorbidities in patients and control groups.
Asthmatic (n = 50) Control (n = 50) t P
Age 9 ±29 .14 ±20 . 2 7 >0.05
BMI 19 ±21 8 .5 ±1.91 . 4 3 >0.05
M/F 1.1:1 01:01.1
Age at diagnosis 3 ±0.9 0 ———
Urban/rural 28:22 (1.27:1) 27:23 (1.17:1)
Associated nasal allergy 27 (54%) 2 (4%) — <0.001∗
Atopic dermatitis 17 (34%) 5 (10%) <0.001∗
Immediate family history of asthma 18 (36%) 1 (2%) — <0.001∗
Smoking parents 1 (2%) 7 (14%)
(∗) P<0.05 is signiﬁcant.
There was no signiﬁcant diﬀerence in age and BMI between asthmatic children and the controls while there was signiﬁcant increase in the incidence of
associated nasal allergy, atopic dermatitis, and family history of asthma in asthmatic children than in the control group. On the other hand the incidence of
smoking parents was higher in control group than in the asthmatic group.
were measured by an enzymatic UV test kit (Roche Diagnos-
tics GmbH, Mannheim, Germany, CAT. no. 11242008001).
At the beginning of the study and at the end of
treatment phase, the patients were assessed (using subjective,
physiological & laboratory assessment) to avoid false positive
or negative results as follows: subjective by childhood-asthma
control Test (C-ACT) for children 4 to 12 years, physiological
by pulmonary functiontest (PFT),and laboratory by sputum
eosinophil and serum Immunoglobulin (Ig) E.
Childhood-Asthma Control Test (C-ACT). The C-ACT is a
7-item child- and caregiver-completed tool with a scoring
range of 0–27; higher scores indicate better control. A score
of 19 or less indicates that the asthma may not be well
controlled. The C-ACT is intended for use in children up to
the age of 12 years [10].
Pulmonary Function Tests (PFT). The children were
weighed, and their heights were measured. Spirometry was
performed for all children in the sitting position using a
calibrated computerized spirometer (SpiroPro, CareFusion,
San Diego, USA). Subjects were required to perform 3 ac-
ceptable Forced Vital Capacity (FVC) manoeuvres according
to American Thoracic Society recommendations [1]. The
maximum percentage in Forced Expiratory Volume in 1
second (FEV1) value from 3 readings was calculated.
TheKasrAlEiniResearchCommitteeapprovedthestudy
protocol. Verbal and written information were given with
full explanation that the trial therapy is just an add-on
therapy not replacing the traditional asthma therapy, and the
children should continue their usual regimen of treatment.
All the families were given the cell phone numbers of the
investigators. They were instructed to call if there was any
s e ri o u ss i d ee ﬀectof the L-Carnitine, any deterioration of the
asthma condition or deterioration of the general condition
of the enrolled child. A fully explained written consent
was signed by the parents of the children who agreed to
participate in the study.
5.2. Statistical Analysis. The primary end point of this trial
was improvement of the lung functions and C-ACT. We
hypothesized that the use of L-Carnitine supplementations
will signiﬁcantly improve the lung functions and C-ACT and
can reduce the severity of inﬂammation in children with
moderate persistent asthma with α level being set to be 0.05.
The power level of the primary end point of the study was
more than 90% and was still more than 85% after excluding
the 27 children who could not complete the study (using:
Power & Precision V3; http://www.Power-Analysis.com/). We
used the paired value and looked at the mean of the results
of each treatment group. Data were presented as mean
(±SD) values. The two-way analysis of variance (ANOVA)
was used to identify statistically signiﬁcant diﬀerences in
the diﬀerent parameters before and after the treatment. For
all analysis, a statistical signiﬁcance of P value <0.05 was
used. The conﬁdence intervals were calculated as indicators
ofstandardizedmeandiﬀerencesbetweengroups.Wilcoxon’s
Signed Rank test was used to assess the normality of
distributions of the data. Correlation between the free and
total serum carnitine level and the severity of asthma was
done. The statistical analysis was performed using TexaSoft,
WINKSSDASoftware,SixthEdition,CedarHill,Texas,2007.
6. Results
Demographic data of the children enrolled in the study were
shown in Table 1. There were no important diﬀerences in
the demographic features of those children who completed
the study versus those who did not. There was no signiﬁcant
diﬀerence between patient and the control group as regard to
age, BMI, and sex. The free and total carnitine serum levels
(Table 2) were signiﬁcantly lower in children with moderate
persistent asthma than in the control group (P<0.001).
Theside eﬀectsof L-Carnitine supplementation encountered
during the study are shown in Table 3. None of these side
eﬀects enforced the children to stop the medication. Table 4
demonstrates a signiﬁcant positive correlation between both
C-ACT and FEV1% predicted and the total and the free4 Journal of Allergy
Table 2: Laboratory ﬁndings in patients and control groups before starting the L-Carnitine therapy.
Asthmatic (n = 50) Control (n = 50) t P
Serum IgE (kU/L) 325 ±103 100.8 ±60.81 3 <0.001∗
Blood eosinophils (%) 5.9 ±2.12 .0 ±0.9 12.5 <0.001∗
Free carnitine (umol/L) 30.3 ±1.83 9 .3 ±3.8 14.5 <0.001∗
Total carnitine (umol/L) 40.1 ±2.64 9 .5 ±3.9 12.8 <0.001∗
(∗) P<0.05 is signiﬁcant.
The table showed serum IgE, blood eosinophils %, free and total serum carnitine in patient and control groups before starting the L-Carnitine therapy.T h e
serum IgE and blood eosinophils were signiﬁcantly higher in asthmatic than in control children. On the other hand, the free and total serum carnitine levels
were signiﬁcantly lower in asthmatic than in control children.
Table 3: Side eﬀects of L-Carnitine treatment.
GIT symptoms 2 (8%)
Stuﬀyn o s e 1( 4 % )
Hyperactivity 1 (4%)
Headache 2 (8%)
Insomnia 0%
Palpitation 0%
Hypertension 0%
Thetableshowedthat,themostencounteredsideeﬀectsofL-Carnitinewere
thegastrointestinaldisordersandheadache.Blockednoseandhyperactivity;
both were recorded in one child. Insomnia, palpitation or hypertension was
not reported. None of these side eﬀects enforced the patients to stop the
intake of the oral L-Carnitine.
serum carnitine level. However, there was no signiﬁcant
correlationbetweentheselevelsandtheFEV1/FVCratiowith
carnitine levels.
Table 5 showed signiﬁcant decrease in the emergency
department visit, total hospital admissions, and blood
eosinophils (%) between children supplemented with L-
Carnitinecomparedtothoseasthmaticchildrenwithplacebo
or before supplementation, while there was no signiﬁcant
diﬀerence in serum IgE levels. Table 6 showed no signiﬁcant
diﬀerence in free and total carnitine serum levels among
patient subgroups before L-Carnitine supplementation (P>
0.05). However, this diﬀerence became signiﬁcant after six
months of oral carnitine supplementation (P> 0.001). The
results of PFT and C-ACT before and after carnitine supple-
mentation are shown in Table 6. There was no signiﬁcant
diﬀerence in PFT and C-ACT between patient subgroups
(subgroup A & B) before L-Carnitine supplementation (P>
0.05). However this diﬀerence became signiﬁcant after 6
monthsofL-CarnitinesupplementationforbothPFTandC-
ACT (P< 0.001). Also there was a signiﬁcant improvement
of both PFT and C-ACT after L-Carnitine supplementation
in the subgroup A children (P<0.001). On the other hand,
when comparing PFT and C-ACT in subgroup B before
and after placebo supplementation, there was no signiﬁcant
improvement in FEV1% predicted and C-ACT. However,
there was signiﬁcant improvement in FEV1/FVC ratio.
7. Discussion
The increased asthma prevalence in the last few decades
is due to diﬀerent factors including changes in the dietary
habits. Carnitine deﬁciency due to fad diets or lack of access
in children may lead to diﬀerent problems including failure
to thrive, recurrent infections, hypotonia, encephalopathy,
cardiomyopathy, or nonketotic hypoglycaemia [11]. Since L-
Carnitine has an essential role in the transport of long-chain
fatty acids through the mitochondrial membrane in order to
ensure eﬃcient β-oxidation of fatty acids, it is important for
activation of pulmonary surfactant synthesis [12].
In the current study, there were signiﬁcant lower free
and total carnitine serum levels in children with moderate
persistent asthma than in the controls. These ﬁndings agreed
with the results of Asilsoy et al. who found that serum
carnitine levels were decreased in children with moderate
asthma during exacerbation of asthma and shortly thereafter
[13]. Whether the decrease in serum carnitine in children
withmoderatepersistentasthmaisacauseoraneﬀect,needs
tobefurtherstudied.InthestudyconductedbyAsilsoyetal.,
they attributed the decrease of serum carnitine levels during
the asthmatic attacks to the decrease in lung surfactant
(during attack) and the use of body stores to replenish it
(after attack).
Carnitine deﬁciency leads to toxic accumulation of long-
chain fatty acids in the cytoplasm and of acyl CoA in the
mitochondria.Theaccumulatedsaturatedandmonounsatu-
rated fats may have diﬀerent eﬀects on airway inﬂammation
[14]. Decreased serum carnitine was also documented in
other respiratory problems like children with recurrent
respiratory tract infections and neonates with respiratory
distress syndrome [15, 16].
From our best knowledge, this study was the ﬁrst to
investigate the beneﬁt of L-Carnitine supplementation in
asthmatic children. In the current study, the PFT and the C-
ACT were signiﬁcantly improved in the asthmatic children
who received L-Carnitine supplementation than in those
who did not (P<0.001). There was also a statistically
signiﬁcant improvement in PFT and C-ACT in subgroup A
patients (who were supplemented with L-Carnitine) when
compared to the presupplementation phase (P<0.001).
TherearenopreviousdataabouttheeﬀectofL-Carnitine
supplementation for asthma management in humans. In the
animal model, Uzuner et al. studied the eﬀect of L-Carnitine
supplementation in mice with laboratory-induced asthma.
They found that L-Carnitine supplementation improved
oxygen saturation and decreased urine leukotriene E4 and
inﬂammation in lung tissues in the studied animals [17].Journal of Allergy 5
Table 4: Correlation between free and total carnitine levels with C-ACT, FEV1% of predicted and FEV1/FVC ratio in asthmatic children at
the beginning of the study.
Variable (n = 50) r 95% CI P
C-ACT
Mean ±SD
13.1 ± 1.43
Total S Carnitine
40.1±2.63 0.36 0.09, 0.58 <0.01∗
Free S Carnitine
30.3 ± 1.8 0.88 0.8, 0.9 <0.001∗
FEV1 (% of predicted)
70.9 ±3.7
Total S Carnitine 0.95 0.91, 0.97 <0.001∗
Free S Carnitine 0.7 0.52, 0.82 <0.001∗
FEV1/FVC
Mean ± SD
60.2 ± 4.5
Total S carnitine 0.26 −0.02, 0.5 >0.05
Free S Carnitine 0.07 −0.2, 0.3 >0.05
C-ACT: Childhood-Asthma control test. FEV1/FVC: Forced Expiratory Volume in 1st second/Forced Vital Capacity Ratio. (∗) P<0.05 is signiﬁcant, r
correlation coeﬃcient, CI conﬁdence interval.
The table showed the correlation between serum carnitine (free and total) and C-ACT and some pulmonary function parameters in asthmatic children at the
beginning of the study. C-ACT and FEV1 (% of predicted) had signiﬁcant positive correlations with total and free serum carnitine. However, there were no
signiﬁcant correlations between FEV1/FVC and the levels of total and free serum carnitine.
Table 5: Emergency room visit, total hospital admissions, blood eosinophils, and serum IgE in patient subgroups before and after carnitine
supplementation and the placebo group.
Subgroup A (with L-Carnitine)
(n = 25)
Subgroup B (Placebo)
(n = 25) t P
Emergency room visit bef. 3.1 ±1.01 3.4 ±1.01 . 2 >0.05
aft 1.5 ±0.62 .6 ±0.94 . 6 8 <0.001∗
Total Hospital admissions bef. 1.5 ±0.61 .8 ±0.71 . 9 >0.05
aft 0.44 ±0.51 .8 ±0.67 . 5 <0.001∗
Oral steroid bef. 2.16 ±0.74 2.12 ±0.72 0.21 >0.05
aft 1.2 ±0.51 .6 ±0.52 . 8 <0.01∗
Serum IgE (kU/L) bef. 328 ±89 322 ±114 0.21 >0.05
aft 253 ±62 290 ±106 1.6 >0.05
Blood eosinophils (%) bef. 5.8 ±2.16 .04 ±2.10 . 3 8 >0.05
aft 3.1 ±0.84 .4 ±1.24 . 2 <0.001∗
(∗) P<0.05 is signiﬁcant There were signiﬁcant decreases in the frequency of emergency room visit, total hospital admissions, and the intake of oral
steroids between L-Carnitine-supplemented children compared to placebo group during the study period. The blood eosinophils % decreased signiﬁcantly
after treatment with L-Carnitine in asthmatic group. It was signiﬁcantly lower in L-Carnitine treatment group than in placebo group. Serum Ig E showedn o
signiﬁcant diﬀerence in treatment and placebo group (both before and after treatment).
The beneﬁcial eﬀect of L-Carnitine in asthmatic children
may be due to diﬀerent mechanisms. It may be due to
its antimicrobial eﬀect, muscle strength eﬀects, enhancing
surfactant synthesis, antileukotriene activity, or through
antagonising the harmful eﬀects of fat on the respiratory
tract. Olgun et al. found an eﬀective antimicrobial eﬀect of
L-Carnitine on diﬀerent bacterial strains. They claimed that
some of the side eﬀects of orally administered L-Carnitine
on gastrointestinal system like diarrhoea could probably be
related to antimicrobial eﬀect on local bacteria [18].
Erg¨ ur et al. found that children with recurrent respi-
ratory tract infections had low serum carnitine level [15].
Respiratory viral infections are important triggers of asthma
attacks [19]. So children with low serum carnitine level may
haverecurrentviralrespiratorytractinfectionsandhenceare
more susceptible to develop asthma. Kavukc ¸u et al. showed
that carnitine can improve exercise tolerance and inspiratory
muscle strength in COPD patients as well as reduce lactate
production and increase rate of lactate removal [7].
Manystudiesproved thatthesurfactantsof theasthmatic
lungsarefunctionallyimpaired.Themainmechanismofthis
impairment was thought to be due to the inﬂux of inhibitory
proteins into the airways, although changes in surfactant
composition may occur [20]. Some studies proved the
beneﬁcial role of L-Carnitine supplementation in improving
the synthesis and the functions of lung surfactants. Kurz
et al., proved the beneﬁcial role of L-Carnitine intake by
pregnant women in decreasing the incidence of respiratory
distress syndrome and even the mortality in premature
newborns. They attributed these eﬀects to the physiological
action of L-Carnitine in surfactant synthesis activation [21].
Leukotrienes are among the mediators of inﬂammation
in asthma and have a strong bronchoconstrictive eﬀect. They
are synthesized in the bronchial mucosa by eosinophils,
basophils, and mast cells. They play an important role
in airway eosinophilic inﬂammation, leukocyte traﬃcking,
airway mucus secretion, airway oedema, collagen synthesis,
and airway remodelling in asthmatic patients [22]. It has6 Journal of Allergy
Table 6: Free and total serum carnitine levels, pulmonary functions, and C-ACT in patient subgroups before and after carnitine
supplementation and the placebo group.
Subgroup A (with L-Carnitine)
(n = 25)
Subgroup B (placebo)
(n = 25) t P
Free carnitine (umol/L) Bef. 30.3 ±1.73 0 .4 ±1.80 . 1 7 >0.05
Aft. 41 ±53 1 ±21 0 <0.001∗
Total carnitine (umol/L) Bef. 39.6 ±2.34 0 .6 ±2.81 . 2 3 >0.05
Aft. 50 ±44 2 ±3 47.56 <0.001∗
FEV1% predicted Bef. 70.5 ±3.27 1 .3 ±4.2 t1 0.66
t2 15
>0.05
<0.001∗
Aft. 76.2 ±3.47 1 .4 ±4.6 t3 3.5
t4 0.96
< 0.01∗
>0.05
FEV1/FVC Bef. 60.1 ±4.56 0 .2 ±4.6 t1 0.8
t2 25
>0.05
<0.001∗
Aft. 71 ±4.46 1 ±4.5 t3 7.3
t4 3.2
<0.001∗
<0.01∗
C-ACT Bef. 13.4 ±1.51 2 .8 ±1.3 t1 1.8
t2 18
>0.05
<0.001∗
Aft 16.5 ±1.71 3 .3 ±1.4 t3 7.1
t4 2.7
<0.001∗
>0.05
C-ACT: Childhood-Asthma control test. FEV1: Forced Expiratory Volume in 1 second. FEV1/FVC: Forced Expiratory Volume in 1st second/Forced Vital
Capacity Ratio.
t1 between subgroup A & subgroup B before carnitine supplementation.
t2 between subgroup A Before & after 6 months of carnitine supplementation.
t3 between subgroup A & subgroup B after 6 months of carnitine supplementation to subgroup A.
t4 between subgroup B before & after 6 months of followup.
(∗) P < 0.05 is signiﬁcant.
There was signiﬁcant increase in total and free serum carnitine levels in L-Carnitine-supplemented group than before starting the treatment and also when
compared with the placebo group. After L-Carnitine supplementation, the pulmonary function tests and C-ACT showed signiﬁcant improvement in the
Carnitine supplemented group when compared to presupplementation or the placebo group. However, the total and free serum carnitine levels did not show
any signiﬁcant change after treatment in placebo group. There was also statistically signiﬁcant improvement in pulmonary function tests and C-ACT in
placebo group before and after treatment.
been reported that L-Carnitine inhibits leukotriene synthesis
by inactivation of lipoxygenase pathway and by altering the
ratio of essential fatty acids. Borghi-silva et al. and Ahmad
et al. demonstrated that L-Carnitine was able to prevent
bronchospasm and improve the obstructive ﬁndings in PFT
in children undergoing chronic haemodialysis [8, 23].
The improvement of FEV1/FVC in the subgroup sup-
plied with placebo treatment was of statistical signiﬁcance
but the improvement was very subtle regarding the ﬁgure.
This may be due to the regular attendance at the clinic and
closer followup and better asthma care during the study
periodorduetothefewsamplecases.Also,FEV1%predicted
is much more important than FEV1/FVC in following the
severity and the improvement of the lung function.
Thelimitationofthestudyisthattheselectionofpatients
was conﬁned to children with moderate persistent asthma.
We did not choose children with mild asthma as they can be
easily controlled, and we did not choose children with severe
asthma as they were too sick to be included in this kind of
trial. Whether the study ﬁnding of carnitine eﬀect can be
applied to other degrees of asthma severity or other asthma
subtypes or phenotypes needs to be further studied.
Another limitation of this study is that we used a ﬁxed
dose of L-Carnitine. A dose eﬀect of L-Carnitine supplement
needs additional studies. An important limitation of the
study is that despite the statistically signiﬁcant improvement
of C-ACT and PFT in the supplemented children, the
children in the active treatment group still had unacceptably
poor asthma control and were in need for more adequate
asthma therapy. It is important to note that the L-Carnitine
was investigated in the current study as add-on therapy and
not replacing any of the traditional asthma medications.
8. Conclusion
L-Carnitine levels were initially lower in moderate persistent
asthmatic children as compared to healthy control children.
Asthmatic children who received L-Carnitine supplementa-
tion showed signiﬁcant statistical improvement of C-ACT
and PFT. The target serum level of L-Carnitine, the eﬀect
of its supplementation in diﬀerent phenotypes and degrees
of asthma severity, and the appropriate dosing need more
studies.
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